Seattle Genetics and Immunomedics to Develop IMMU-132 for Triple Negative Breast Cancer, Other Solid Tumors

Seattle Genetics and Immunomedics to Develop IMMU-132 for Triple Negative Breast Cancer, Other Solid Tumors
Seattle Genetics and Immunomedics are collaborating to develop and market IMMU-132, currently being studied for the treatment of triple negative breast cancer and other solid tumors. Under the terms of the licensing agreement, Seattle Genetics will get the exclusive rights develop, manufacture, and commercialize the antibody-drug conjugate sacituzumab govitecan (IMMU-132). Once the agreement is finalized, Seattle Genetics will make an upfront payment of $250 million to Immunomedics, and fund all development, regulatory, and sales-dependent payments up to $1.7 billion. “After a long and robust process, we concluded that licensing our lead asset, sacituzumab govitecan, to Seattle Genetics, the leading ADC [antibody-drug conjugate] company, would give us the best opportunity to advance this product on behalf of advanced stage cancer patients," Cynthia L. Sullivan, president and CEO of Immunomedics, said in a news release. "Sacituzumab govitecan has the potential to drive significant value for patients with multiple types of cancer who are in need of new therapy options, and we look forward to continuing its development with Seattle Genetics,” she said. IMMU-132 is composed of an anti-TROP-2 antibody linked to an active metabolite of ironotecan, SN-38. TROP-2 is found in many tumor types, including breast, colon, lung and bladder cancers. Data from a Phase 1/2 trial in metastatic triple negative breast cancer patients showed an objective response rate of 29 percent, with a median duration of response of 10.8 months. In addition, p
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.